-
Strengthening SEA regional cooperation to tackle Multiple Myeloma (MM) through early diagnosis and treatment
29 Apr 2025 19:10 GMT
… , from Bortezomib, in partnership with Millennium Pharmaceuticals, to Daratumumab, improve outcomes in …
-
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
29 Apr 2025 11:14 GMT
… in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary …
-
Pevonedistat hydrochloride by Millennium Pharmaceuticals for Essential Thrombocythemia: Likelihood of Approval
27 Oct 2023 16:35 GMT
… the below form
By GlobalData
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary …
-
Ixazomib citrate by Millennium Pharmaceuticals for Lymphoblastic Lymphoma: Likelihood of Approval
27 Oct 2023 16:35 GMT
… and graft versus host disease.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals (Takeda Oncology), a subsidiary …
-
Pevonedistat hydrochloride by Millennium Pharmaceuticals for Solid Tumor: Likelihood of Approval
10 Feb 2023 09:11 GMT
… is under clinical development by Millennium Pharmaceuticals and currently in Phase I … refractory acute lymphocytic leukemia.
Millennium Pharmaceuticals overview
Millennium Pharmaceuticals is a biopharmaceutical company that …
-
Colombia to Columbia: A Quest for Better Myeloma Outcomes
04 Apr 2025 13:07 GMT
… , Celgene, Janssen, Karyopharm Therapeutics, and Millennium Pharmaceuticals.
-
Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer
01 Apr 2025 12:20 GMT
… , Dr. Bolen was CSO at Millennium Pharmaceuticals and Global Head of Oncology …
-
Alvotech Reports Record Results for 2024 and Provides Business Update
26 Mar 2025 22:34 GMT
… . Entyvio is a trademark of Millennium Pharmaceuticals, Inc. Xolair is a registered …
-
CABLIVI Market Reports Positive Growth - Strong Momentum Expected to Continue | DelveInsight
20 Mar 2025 00:15 GMT
… , Principia Biopharma, Baxalta, Takeda, Argenx, Millennium Pharmaceuticals, Biotest, GC Pharma, Genosco (Subsidiary …
-
Shift Bioscience Announces Key Appointments to Advance Rejuvenation Therapeutics Pipeline
12 Mar 2025 10:32 GMT
… roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. Now focusing his expertise in …